Poland – Delivery of the medicinal product Nivolumab + Relatlimab, PN-166/26/TM

By: National Institute of OncologyMaria Skłodowska-Curie - National Research Institute📍 PolandOpen

Key Information

ReferenceGB-803177-2026
DeadlineDec 18, 2026 12:00 AM
CategoryAdvertising & Media
Competition TypeICB
Funding SourceSelf-Funded
CountryPoland
AddressstreetW. K. Roentgena 5, Warsaw, 02-781, Poland
PublishedNov 18, 2026

Description

2. Procedure2.1.ProcedureTitle: Dostawa produktu leczniczego Niwolumab + Relatlimab, PN-166/26/TMDescription: 1. Przedmiotem zamówienia jest dostawa produktu leczniczego Niwolumab + Relatlimab.2. Szcz...

Full details are available after unlocking this tender.